Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -96.68% | -- | 132.66% | -- | 1,547.72% |
| Total Depreciation and Amortization | -22.87% | -- | -16.37% | -- | -51.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 93.89% | -- | -362.67% | -- | -4,844.16% |
| Change in Net Operating Assets | -350.55% | -- | -81.34% | -- | 77.90% |
| Cash from Operations | 1.52% | -- | 22.85% | 39.44% | 5.45% |
| Capital Expenditure | -414.65% | -- | -139.45% | -- | 30.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -97.05% | -- | -- | -- | 169,410.77% |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -91.32% | -- | -1,019.05% | -93.90% | 149,147.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -540.71% | -- | 76.58% | -- | -3.22% |
| Issuance of Common Stock | 216.57% | -- | -89.20% | -- | -90.68% |
| Repurchase of Common Stock | -7,505.64% | -- | -11,410.67% | -- | -197.66% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 252.49% |
| Cash from Financing | -215.34% | -- | -8,935.31% | -115.51% | 53.17% |
| Foreign Exchange rate Adjustments | -135.08% | -- | -2,241.88% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.52% | -- | -253.51% | -189.36% | 7,448.62% |
